Complement Inhibitors for Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy): Some Light at the End of the Tunnel?

M Cruz-Pimentel, L Wu - Journal of Clinical Medicine, 2023 - mdpi.com
Geographic atrophy (GA) affects around 5 million individuals worldwide. Genome-wide,
histopathologic, in vitro and animal studies have implicated the activation of the complement …

AI in the clinical management of GA: a novel therapeutic universe requires novel tools

GS Reiter, J Mai, S Riedl, K Birner, S Frank… - Progress in Retinal and …, 2024 - Elsevier
Regulatory approval of the first two therapeutic substances for the management of
geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a major …

[HTML][HTML] Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning

WD Vogl, S Riedl, J Mai, GS Reiter, D Lachinov… - Ophthalmology …, 2023 - Elsevier
Purpose To identify disease activity and effects of intravitreal pegcetacoplan treatment on
the topographic progression of geographic atrophy (GA) secondary to age-related macular …

[HTML][HTML] Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT

U Schmidt-Erfurth, J Mai, GS Reiter, S Riedl, WD Vogl… - Ophthalmology, 2024 - Elsevier
Purpose To quantify morphological changes of the photoreceptors (PRs) and retinal pigment
epithelium (RPE) layers under pegcetacoplan therapy in geographic atrophy (GA) using …

The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis

A Garg, K Nanji, F Tai, M Phillips, D Zeraatkar… - Survey of …, 2024 - Elsevier
With the introduction of therapies to treat geographic atrophy (GA), GA management in
clinical practice is now possible. A living systematic review can provide access to timely and …

Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment

J Mai, D Lachinov, S Riedl, GS Reiter, WD Vogl… - Scientific Reports, 2023 - nature.com
Geographic atrophy (GA) represents a late stage of age-related macular degeneration,
which leads to irreversible vision loss. With the first successful therapeutic approach, namely …

Deep-learning-based automated measurement of outer retinal layer thickness for use in the assessment of age-related macular degeneration, applicable to both …

J Lu, Y Cheng, FE Hiya, M Shen, G Herrera… - Biomedical optics …, 2023 - opg.optica.org
Effective biomarkers are required for assessing the progression of age-related macular
degeneration (AMD), a prevalent and progressive eye disease. This paper presents a deep …

Unleashing the power of optical attenuation coefficients to facilitate segmentation strategies in OCT imaging of age-related macular degeneration: perspective

PJ Rosenfeld, Y Cheng, M Shen, G Gregori… - Biomedical optics …, 2023 - opg.optica.org
The use of optical attenuation coefficients (OAC) in optical coherence tomography (OCT)
imaging of the retina has improved the segmentation of anatomic layers compared with …

Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy

M Pfau, S Schmitz-Valckenberg, R Ribeiro, R Safaei… - Scientific Reports, 2022 - nature.com
Preservation of photoreceptors beyond areas of retinal pigment epithelium atrophy is a
critical treatment goal in eyes with geographic atrophy (GA) to prevent vision loss. Thus, we …

[HTML][HTML] Vision loss reduction with avacincaptad pegol for geographic atrophy: a 12-month post hoc analysis of the GATHER1 and GATHER2 trials

CJ Danzig, AM Khanani, PK Kaiser, MA Chang… - Ophthalmology …, 2024 - Elsevier
Purpose To evaluate the impact of reduction in geographic atrophy (GA) lesion growth on
visual acuity in the GATHER trials using categorical outcome measures. Design …